STOCK TITAN

Scilex Holding (NASDAQ: SCLX) raises non-recourse loan from $50M to $100M

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Scilex Holding Company amended its non-recourse Loan and Securities Pledge Agreement with The St. James Bank & Trust Company Ltd., increasing the total principal available from $50 million to $100 million.

To support the larger facility, the company increased the pledged collateral in Datavault AI Inc. from approximately 39.2 million to 85.8 million shares of Datavault common stock. All other terms of the original loan agreement remain in effect, so this change primarily expands the amount Scilex can borrow against its Datavault stake.

Positive

  • None.

Negative

  • None.

Insights

Scilex doubles non-recourse loan capacity to $100 million by pledging more Datavault AI shares.

Scilex Holding Company amended its non-recourse Loan and Securities Pledge Agreement with The St. James Bank & Trust Company Ltd. on December 8, 2025. The amendment raises the aggregate principal available from $50 million to $100 million, giving Scilex access to a larger borrowing facility under the same non-recourse structure.

In exchange, Scilex increased the pledged collateral from approximately 39.2 million to 85.8 million shares of Datavault AI Inc. common stock. This ties a larger portion of its Datavault stake to the loan, while the filing states that all other terms of the original agreement continue in full force and effect.

From a capital structure perspective, the key elements are the higher potential debt size, the non-recourse nature of the borrowing, and the significantly expanded Datavault share pledge securing the facility.

0001820190false0001820190sclx:WarrantsToPurchaseOneShareOfCommonStockEachAtAnExercisePriceOf40250PerShareMember2025-12-082025-12-0800018201902025-12-082025-12-080001820190sclx:CommonStockParValue00001PerShare2Member2025-12-082025-12-08

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

_______________________

FORM 8-K
_______________________

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): December 8, 2025

_______________________

SCILEX HOLDING COMPANY
(Exact name of registrant as specified in its charter)

_______________________

Delaware
(State or other jurisdiction
of incorporation)

001-39852
(Commission
File Number)

92-1062542
(IRS Employer
Identification No.)

 

960 San Antonio Road, Palo Alto, California, 94303
(Address of principal executive offices, including zip code)

(650) 516-4310

Registrant’s telephone number, including area code

N/A
(Former Name or Former Address, if Changed Since Last Report)

_______________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

 

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

 

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

 

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Exchange Act:

(Title of each class)

(Trading Symbol)

(Name of exchange on which registered)

Common Stock, par value $0.0001 per share

SCLX

The Nasdaq Stock Market LLC

Warrants to purchase one share of common stock, each at an exercise price of $402.50

SCLXW

The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


 

Item 1.01. Entry into a Material Definitive Agreement

As previously disclosed, on December 1, 2025, Scilex Holding Company (the “Company”) entered into a Non-Recourse Loan and Securities Pledge Agreement (the “Loan Agreement”) with The St. James Bank & Trust Company Ltd., a corporation existing under the laws of the Bahamas (the “Lender”), pursuant to which the Lender agreed to loan the Company an aggregate principal amount of up to $50 million in one or more tranches (the “Loan”). Pursuant to the terms of the Loan Agreement, the Company agreed to pledge approximately 39.2 million shares of common stock of Datavault AI Inc. (“Datavault”) currently held by Scilex (the “Pledged Securities”) in favor of the Lender as security for the Company’s satisfaction of its obligations thereunder.

On December 8, 2025 the Company and the Lender entered into an amendment to the Loan Agreement (the “Loan Amendment”) pursuant to which the total aggregate principal amount available under the Loan Agreement was increased to $100 million. Additionally, the amount of Pledged Securities was increased to 85.8 million shares of common stock of Datavault. All other terms of the Loan Agreement will continue in full force and effect unamended.

The foregoing summary of the Loan Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Loan Amendment, a copy of which is filed herewith as Exhibit 10.1 and is incorporated herein by reference.

 

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

 

The information set forth under Item 1.01 above relating to the Loan Amendment is incorporated by reference herein.

 

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit
Number

Description

10.1

Amendment to Non-Recourse Loan and Securities Pledge Agreement, dated December 8, 2025, by and between Scilex Holding Company and The St. James Bank & Trust Company Ltd.

104

Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

 

2

 


 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

SCILEX HOLDING COMPANY

 

 

 

 

By:

/s/ Henry Ji

 

Name:

Henry Ji

Date: December 12, 2025

Title:

Chief Executive Officer & President

 

3

 


FAQ

What change did Scilex Holding Company (SCLX) make to its loan agreement?

Scilex Holding Company amended its non-recourse Loan and Securities Pledge Agreement with The St. James Bank & Trust Company Ltd., increasing the total principal available from $50 million to $100 million.

How large is Scilex Holding Companys non-recourse loan facility after the amendment?

After the amendment, Scilex can borrow up to $100 million in aggregate principal under the non-recourse loan agreement.

What collateral secures Scilex Holding Companys amended non-recourse loan?

The loan is secured by 85.8 million shares of Datavault AI Inc. common stock pledged by Scilex as collateral.

How did the pledged Datavault AI Inc. shares change in this amendment for SCLX?

The pledged Datavault AI Inc. common stock increased from approximately 39.2 million shares to 85.8 million shares under the amended agreement.

Did Scilex Holding Company change any other terms of the loan agreement?

No other terms were changed; the amendment states that all other terms of the original Loan and Securities Pledge Agreement remain in full force and effect.

Who is the lender under Scilex Holding Companys non-recourse loan facility?

The lender is The St. James Bank & Trust Company Ltd., a corporation organized under the laws of the Bahamas.

Scilex Holding Co

NASDAQ:SCLX

SCLX Rankings

SCLX Latest News

SCLX Latest SEC Filings

SCLX Stock Data

102.75M
7.00M
21.43%
78.14%
7.66%
Drug Manufacturers - General
Biological Products, (no Disgnostic Substances)
Link
United States
PALO ALTO